Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 4D Molecular Therapeutics Inc FDMT

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular... see more

Recent & Breaking News (NDAQ:FDMT)

4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity

GlobeNewswire July 17, 2024

4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy

GlobeNewswire June 24, 2024

4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast

GlobeNewswire June 18, 2024

4D MOLECULAR INVESTOR ALERT: Kaskela Law LLC Announces Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm

Accesswire June 11, 2024

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

GlobeNewswire June 8, 2024

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference

GlobeNewswire June 6, 2024

4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting

GlobeNewswire June 4, 2024

4DMT to Participate in Upcoming Investor Conferences

GlobeNewswire June 3, 2024

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference

GlobeNewswire May 30, 2024

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

GlobeNewswire May 9, 2024

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of 4D Molecular Therapeutics, Inc. (FDMT) and Encourages Investors to Contact the Firm

Accesswire May 8, 2024

4DMT to Participate in Upcoming Investor Conference

GlobeNewswire May 7, 2024

4DMT Announces Presentations at ARVO 2024 Annual Meeting

GlobeNewswire May 1, 2024

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

GlobeNewswire March 28, 2024

4DMT to Participate in Upcoming Investor Conferences

GlobeNewswire March 4, 2024

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

GlobeNewswire February 29, 2024

4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium(TM) 2024

GlobeNewswire February 12, 2024

4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

GlobeNewswire February 6, 2024

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire February 5, 2024

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

GlobeNewswire February 3, 2024